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Abstract
Comparative effectiveness research compares two active forms of treatment or usual care in comparison with usual
care with an additional intervention element. These types of study are commonly conducted following a placebo
or no active treatment trial. Research designs with a placebo or non-active treatment arm can be challenging for
the clinician researcher when conducted within the healthcare environment with patients attending for treatment.
A framework for conducting comparative effectiveness research is needed, particularly for interventions for which
there are no strong regulatory requirements that must be met prior to their introduction into usual care.
We argue for a broader use of comparative effectiveness research to achieve translatable real-world clinical
research. These types of research design also affect the rapid uptake of evidence-based clinical practice within
the healthcare setting.
This framework includes questions to guide the clinician researcher into the most appropriate trial design to
measure treatment effect. These questions include consideration given to current treatment provision during
usual care, known treatment effectiveness, side effects of treatments, economic impact, and the setting in
which the research is being undertaken.
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Background
Comparative effectiveness research compares two active
forms of treatment or usual care in comparison with
usual care with an additional intervention element.
Comparative effectiveness research differs from study
designs that have an inactive control, such as a ‘no-inter-
vention’ or placebo group. In pharmaceutical research,
trial designs in which placebo drugs are tested against
the trial medication are often labeled ‘Phase III’ trials.
Phase III trials aim to produce high-quality evidence of
intervention efficacy and are important to identify po-
tential side effects and benefits. Health outcome research
with this study design involves the placebo being non-
treatment or a ‘sham’ treatment option [1].
Traditionally, comparative effectiveness research is
conducted following completion of a Phase III placebo
control trial [2–4]. It is possible that comparative effect-
iveness research might not determine whether one treat-
ment has clinical beneficence, because the comparator
treatment might be harmful, irrelevant, or ineffective.
This is unless the comparator treatment has already
demonstrated superiority to a placebo [2]. Moreover,
comparing an active treatment to an inactive control will
be more likely to produce larger effect sizes than a com-
parison of two active treatments [5], requiring smaller
sample sizes and lower costs to establish or refute the ef-
fectiveness of a treatment. Historically, then, treatments
only become candidates for comparative effectiveness re-
search to establish superiority, after a treatment has
demonstrated efficacy against an inactive control.
Frequently, the provision of health interventions pre-
cedes development of the evidence base directly sup-
porting their use [6]. Some service-provision contexts
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are highly regulated and high standards of evidence are
required before an intervention can be provided (such as
pharmacological interventions and device use). However,
this is not universally the case for all services that may
be provided in healthcare interventions. Despite this,
there may be expectation from the individual patient
and the public that individuals who present to a health
service will receive some form of care deemed appropri-
ate by treating clinicians, even in the absence of
research-based evidence supporting this. This expect-
ation may be amplified in publicly subsidized health ser-
vices (as is largely the case in Canada, the UK, Australia,
and many other developed nations) [7–9]. If a treatment
is already widely employed by health professionals and is
accepted by patients as a component of usual care, then
it is important to consider the ethics and practicality of
attempting a placebo or no-intervention control trial in
this context. In this context, comparative effectiveness
research could provide valuable insights to treatment
effectiveness, disease pathophysiology, and economic
efficiency in service delivery, with greater research feasi-
bility than the traditional paradigm just described. Fur-
ther, some authors have argued that studies with inactive
control groups are used when comparative effectiveness
research designs are more appropriate [10]. We propose
and justify a framework for conducting research that
argues for the broader use of comparative effectiveness
research to achieve more feasible and translatable real-
world clinical research.
This debate is important for the research community;
particularly those engaged in the planning and execu-
tion of research in clinical practice settings, particularly
in the provision of non-pharmacological, non-device
type interventions. The ethical, preferential, and prag-
matic implications from active versus inactive compara-
tor selection in clinical trials not only influence the
range of theoretical conclusions that could be drawn
from a study, but also the lived experiences of patients
and their treating clinical teams. The comparator selec-
tion will also have important implications for policy and
practice when considering potential translation into
clinical settings. It is these implications that affect the
clinical researcher’s methodological design choice and
justification.
Framework
The decision-making framework takes the form of a de-
cision tree (Fig. 1) to determine when a comparative ef-
fectiveness study can be justified and is particularly
relevant to the provision of services that do not have a
tight regulatory framework governing when an interven-
tion can be used as part of usual care. This framework is
headed by Level 1 questions (demarcated by a question
within an oval), which feed into decision nodes (demar-
cated by rectangles), which end in decision points (de-
marcated by diamonds). Each question is discussed with
clinical examples to illustrate relevant points.
Treatment A is any treatment for a particular condi-
tion that may or may not be a component of usual care
to manage that condition. Treatment B is our treatment
of interest. The framework results in three possible rec-
ommendations: that either (i) a study design comparing
Treatment B with no active intervention could be used,
or (ii) a study design comparing Treatment A, Treat-
ment B and no active intervention should be used, or
(iii) a comparative effectiveness study (Treatment A ver-
sus Treatment B) should be used.
Level 1 questions
Is the condition of interest being managed by any
treatment as part of usual care either locally or
internationally?
Researchers first need to identify what treatments are
being offered as usual care to their target patient popula-
tion to consider whether to perform a comparative
effectiveness research (Treatment A versus B) or use a
Fig. 1 Comparative effectiveness research decision-making framework. Treatment A represents any treatment for a particular condition, which
may or may not be a component of usual care to manage that condition. Treatment B is used to represent our treatment of interest. Where the
response is unknown, the user should choose the NO response
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design comparing Treatment B with an inactive control.
Usual care has been shown to vary across healthcare set-
tings for many interventions [11, 12]; thus, researchers
should understand that usual care in their context might
not be usual care universally. Consequently, researchers
must consider what comprises usual care both in their
local context and more broadly.
If there is no usual care treatment, then it is practical
to undertake a design comparing Treatment B with no
active treatment (Fig. 1, Exit 1). If there is strong evi-
dence of treatment effectiveness, safety, and cost-
effectiveness of Treatment A that is not a component of
usual care locally, this treatment should be considered
for inclusion in the study. This situation can occur from
delayed translation of research evidence into practice,
with an estimated 17 years to implement only 14 % of
research in evidence-based care [13]. In this circum-
stance, although it may be more feasible to use a Treat-
ment B versus no active treatment design, the value of
this research will be very limited, compared with com-
parative effectiveness research of Treatment A versus B.
If the condition is currently being treated as part of
usual care, then the researcher should consider the alter-
nate Level 1 question for progression to Level 2.
As an example, prevention of falls is a safety priority
within all healthcare sectors and most healthcare ser-
vices have mitigation strategies in place. Evaluation of
the effectiveness of different fall-prevention strategies
within the hospital setting would most commonly re-
quire a comparative design [14]. A non-active treatment
in this instance would mean withdrawal of a service that
might be perceived as essential, a governmental health
priority, and already integrated in the healthcare system.
Is there evidence of Treatment A’s effectiveness
compared with no active intervention beyond usual care?
If there is evidence of Treatment A’s effectiveness com-
pared with a placebo or no active treatment, then we
progress to Question 3. If Treatment A has limited evi-
dence, a comparative effectiveness research design of
Treatment B versus no active treatment design can be
considered. By comparing Treatment A with Treatment
B, researchers would generate relevant research evidence
for their local healthcare setting (is Treatment B super-
ior to usual care or Treatment A?) and other healthcare
settings that use Treatment A as their usual care. This
design may be particularly useful when the local popula-
tion is targeted and extrapolation of research findings is
less relevant.
For example, the success of chronic disease manage-
ment programs (Treatment A) run in different Aborigi-
nal communities were highly influenced by unique
characteristics and local cultures and traditions [15].
Therefore, taking Treatment A to an urban setting or
non-indigenous setting with those unique characteristics
will render Treatment A ineffectual. The use of Treat-
ment A may also be particularly useful in circumstances
where the condition of interest has an uncertain etiology
and the competing treatments under consideration ad-
dress different pathophysiological pathways. However, if
Treatment A has limited use beyond the research loca-
tion and there are no compelling reasons to extrapolate
findings more broadly applicable, then Treatment B ver-
sus no active control design may be suitable.
The key points clinical researchers should consider are:
 The commonality of the treatment within usual care
 The success of established treatments in localized or
unique population groups only
 Established effectiveness of treatments compared
with placebo or no active treatment
Level 2 questions
Do the benefits of Treatment A exceed the side effects
when compared with no active intervention beyond
usual care?
Where Treatment A is known to be effective, yet pro-
duces side effects, the severity, risk of occurrence, and
duration of the side effects should be considered before
it is used as a comparator for Treatment B. If the risk or
potential severity of Treatment A is unacceptably high
or is uncertain, and there are no other potential com-
parative treatments available, a study design compar-
ing Treatment B with no active intervention should be
used (Fig. 1, Exit 2). Whether Treatment A remains a
component of usual care should also be considered. If
the side effects of Treatment A are considered accept-
able, comparative effectiveness research may still be
warranted.
The clinician researcher may also be challenged when
the risk of the Treatment A and risk of Treatment B are
unknown or when one is marginally more risky than the
other [16]. Unknown risk comparison between the two
treatments when using this framework should be consid-
ered as uncertain and the design of Treatment A versus
Treatment B or Treatment B versus no intervention or a
three-arm trial investigating Treatment A, B and no
intervention is potentially justified (Fig. 1, Exit 3).
A good example of risk comparison is the use of exer-
cise programs. Walking has many health benefits, par-
ticularly for older adults, and has also demonstrated
benefits in reducing falls [17]. Exercise programs inclu-
sive of walking training have been shown to prevent falls
but brisk walking programs for people at high risk of
falls can increase the number of falls experienced [18].
The pragmatic approach of risk and design of compara-
tive effectiveness research could better demonstrate the
effect than a placebo (no active treatment) based trial.
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The key points clinical researchers should consider are:
 Risk of treatment side effects (including death) in
the design
 Acceptable levels of risk are present for all
treatments
Level 3 question
Does Treatment A have a sufficient overall net benefit,
when all costs and consequences or benefits are
considered to deem it superior to a ‘no active
intervention beyond usual care’ condition?
Simply being effective and free of unacceptable side
effects is insufficient to warrant Treatment A being
the standard for comparison. If the cost of providing
Treatment A is so high that it renders its benefits in-
significant compared with its costs, or Treatment A
has been shown not to be cost-effective, or the cost-
effectiveness is below acceptable thresholds, it is clear
that Treatment A is not a realistic comparator. Some
have advocated for a cost-effectiveness (cost-utility)
threshold of $50,000 per quality-adjusted life year
gained as being an appropriate threshold, though
there is some disagreement about this and different
societies might have different capacities to afford such
a threshold [19]. Based on these considerations, one
should further contemplate whether Treatment A
should remain a component of usual care. If no other
potential comparative treatments are available, a study
design comparing Treatment B with no active inter-
vention is recommended (Fig. 1, Exit 4).
If Treatment A does have demonstrated efficacy, safety,
and cost-effectiveness compared with no active treatment,
it is unethical to pursue a study design comparing Treat-
ment B with no active intervention, where patients provid-
ing consent are being asked to forego a safe and effective
treatment that they otherwise would have received. This is
an unethical approach and also unfeasible, as the recruit-
ment rates could be very poor. However, Treatment A
may be reasonable to include as a comparison if it is usu-
ally purchased by the potential participant and is made
available through the trial.
The methodological design of a diabetic foot wound
study illustrates the importance of health economics
[20]. This study compared the outcomes of Treatment A
(non-surgical sharps debridement) with Treatment B
(low-frequency ultrasonic debridement). Empirical evi-
dence supports the need for wound care and non-
intervention would place the patient at risk of further
wound deterioration, potentially resulting in loss of limb
loss or death [21]. High consumable expenses and in-
creased short-term time demands compared with low
expense and longer term decreased time demands must
also be considered. The value of information should also
be considered, with the existing levels of evidence
weighed up against the opportunity cost of using re-
search funds for another purpose in the context of the
probability that Treatment A is cost-effective [22].
The key points clinical researchers should consider are:
 Economic evaluation and effect on treatment
 Understanding the health economics of treatment
based on effectiveness will guide clinical practice
 Not all treatment costs are known but
establishing these can guide evidence-based
practice or research design
Level 4 question
Is the patient (potential participant) presenting to a
health service or to a university- or research-administered
clinic?
If Treatment A is not a component of usual care, one
of three alternatives is being considered by the re-
searcher: (i) conducting a comparative effectiveness
study of Treatment B in addition to usual care versus
usual care alone, (ii) introducing Treatment A to
usual care for the purpose of the trial and then com-
paring it with Treatment B in addition to usual care,
(iii) conducting a trial of Treatment B versus no ac-
tive control. If the researcher is considering option
(i), usual care should itself be considered to be Treat-
ment A, and the researcher should return to Question
2 in our framework.
There is a recent focus on the importance of health
research conducted by clinicians within health service
settings as distinct from health research conducted by
university-based academics within university settings
[23, 24]. People who present to health services expect to
receive treatment for their complaint, unlike a person
responding to a research trial advertisement, where it is
clearly stated that participants might not receive active
treatment. It is in these circumstances that option (ii) is
most appropriate.
Using research designs (option iii) comparing Treat-
ment B with no active control within a health service
setting poses challenges to clinical staff caring for pa-
tients, as they need to consider the ethics of enrolling
patients into a study who might not receive an active
treatment (Fig. 1, Exit 4). This is not to imply that the
use of a non-active control is unethical. Where there is
no evidence of effectiveness, this should be considered
within the study design and in relation to the other
framework questions about the risk and use of the treat-
ment within usual care. Clinicians will need to establish
the effectiveness, safety, and cost-effectiveness of the
treatments and their impact on other health services,
weighed against their concern for the patient’s well-
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being and the possibility that no treatment will be pro-
vided [25]. This is referred to as clinical equipoise.
Patients have a right to access publicly available
health interventions, regardless of the presence of a
trial. Comparing Treatment B with no active control
is inappropriate, owing to usual care being withheld.
However, if there is insufficient evidence that usual
care is effective, or sufficient evidence that adverse
events are likely, the treatment is prohibitive to im-
plement within clinical practice, or the cost of the
intervention is significant, a sham or placebo-based
trial should be implemented.
Comparative effectiveness research evaluating differ-
ent treatment options of heel pain within a commu-
nity health service [26] highlighted the importance of
the research setting. Children with heel pain who
attended the health service for treatment were re-
cruited for this study. Children and parents were
asked on enrollment if they would participate if there
were a potential assignment to a ‘no-intervention’
group. Of the 124 participants, only 7 % (n = 9) agreed
that they would participate if placed into a group with
no treatment [26].
The key points clinical researchers should consider are:
 The research setting can impact the design of
research
 Clinical equipoise challenges clinicians during
recruitment into research in the healthcare setting
 Patients enter a healthcare service for treatment;
entering a clinical trial is not the presentation
motive
Conclusion
This framework describes and examines a decision
structure for comparator selection in comparative ef-
fectiveness research based on current interventions,
risk, and setting. While scientific rigor is critical,
researchers in clinical contexts have additional con-
siderations related to existing practice, patient safety,
and outcomes. It is proposed that when trials are
conducted in healthcare settings, a comparative ef-
fectiveness research design should be the preferred
methodology to placebo-based trial design, provided
that evidence for treatment options, risk, and setting
have all been carefully considered.
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